Tesamorelin Guide

Tesamorelin is a synthetic analog of growth hormone-releasing factor, also called growth hormone-releasing hormone. In the United States, FDA-approved tesamorelin products are marketed under EGRIFTA formulations for a narrow HIV-associated lipodystrophy indication, not for general weight loss or cosmetic body composition use. [1][2]

The key distinction is that tesamorelin has real human trial and labeling history, but that evidence is population-specific. Most pivotal work studied adults with HIV, stable antiretroviral therapy, and excess abdominal or visceral fat. Those results should not be generalized to healthy users, bodybuilding settings, or research-chemical products. [1][3][4][5]

Current labels distinguish between EGRIFTA WR and EGRIFTA SV. They have different strengths, preparation requirements, and storage rules, and the WR label states that the products are not substitutable. This profile treats tesamorelin as a regulated prescription drug topic, not as one interchangeable vial format. [1][2]

Official labeling describes tesamorelin as a growth hormone-releasing factor analog. Mechanistically, it stimulates pituitary growth hormone secretion, which then increases downstream insulin-like growth factor 1 signaling and affects lipid metabolism. That is different from giving recombinant growth hormone directly. [1][2]

The mechanism is relevant because growth hormone biology can affect visceral adipose tissue, fluid balance, glucose handling, and IGF-1. Those same pathways explain why the label includes monitoring and safety concerns rather than treating tesamorelin as a simple fat-loss supplement. [1][2][4]

The approved indication is focused on excess abdominal fat in HIV-associated lipodystrophy. The label also says EGRIFTA products have a weight-neutral effect and are not indicated for weight loss management, so online claims about broad weight loss should be interpreted carefully. [1][2]

EGRIFTA SV labeling states that it is indicated for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The same labeling lists limitations: long-term cardiovascular safety has not been established, it is not indicated for weight loss management, and there are no data showing improved compliance with antiretroviral therapies. [2]

EGRIFTA WR is a newer tesamorelin formulation with its own prescribing information. Its label repeats the same narrow indication and notes that the WR and SV formulations differ in strength, preparation, number of vials, and storage requirements. [1]

The clinical evidence base includes randomized controlled studies in adults with HIV and excess abdominal fat. A 2007 New England Journal of Medicine trial reported greater reduction in visceral adipose tissue with tesamorelin than placebo over 26 weeks, with the endpoint assessed by imaging rather than by scale weight alone. [3]

A later randomized placebo-controlled trial with a safety extension also reported significant visceral adipose tissue reduction over six months and maintenance of effect in participants who continued therapy; participants who switched from tesamorelin to placebo lost much of the improvement. [4]

A pooled phase 3 analysis provides broader context across two multicenter trials and extension data. It supports the VAT-reduction signal in the studied HIV population while also reinforcing that the evidence is tied to monitored clinical trial settings. [5]

The most consistent benefit discussed in pivotal tesamorelin trials is reduced visceral adipose tissue, or VAT. VAT is deep abdominal fat around internal organs and is different from subcutaneous fat directly under the skin. Trial results should therefore not be read as a guarantee of visible cosmetic fat loss. [3][4][5]

Trials also reported changes in waist measures and some body-image or belly-appearance distress measures. Those findings are relevant to the approved lipodystrophy context, but they do not establish tesamorelin as a general wellness, anti-aging, or bodybuilding drug. [4][5]

In a randomized JAMA trial in HIV-infected adults with abdominal fat accumulation, tesamorelin reduced visceral fat and liver fat over six months compared with placebo. This supports biologic interest in ectopic fat, but it is still a defined research population rather than a broad consumer indication. [6]

More recent analyses have continued to examine tesamorelin in people with HIV and metabolic complications, including people using integrase inhibitors. These data help refine the evidence base but do not remove the need to follow approved labeling and clinician supervision. [7]

Tesamorelin labels include contraindications for disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or excipients, and pregnancy. Those exclusions matter because the drug works through a growth hormone pathway. [1][2]

Warnings include increased risk of neoplasms, elevated IGF-1, fluid retention, glucose intolerance or diabetes mellitus, hypersensitivity reactions, injection-site reactions, and increased mortality in patients with acute critical illness. These are label-level safety issues, not rare internet footnotes. [1][2]

Common adverse reactions listed in the EGRIFTA WR label include arthralgia, injection-site erythema, injection-site pruritus, pain in extremity, peripheral edema, and myalgia. EGRIFTA SV labeling also emphasizes monitoring for glucose changes and persistent IGF-1 elevation. [1][2]

The safety profile in clinical trials does not make unapproved products equivalent to FDA-approved tesamorelin. Non-approved vials may differ in identity, purity, sterility, concentration, excipients, and handling, and this profile does not provide compounding or reconstitution guidance. [1][2]

Storage rules are formulation-specific. EGRIFTA WR and EGRIFTA SV should not be treated as interchangeable because their labels describe different formulation strengths, preparation requirements, and storage instructions. [1][2]

EGRIFTA WR labeling says to store the medication and injection boxes at room temperature, 68 to 77 degrees F or 20 to 25 degrees C, and to keep vials out of the light. After mixing with the provided bacteriostatic water, the label says not to freeze or refrigerate the product. [1]

EGRIFTA SV labeling says to store the 2 mg vials, sterile water, syringes, and needles at room temperature, keep vials out of the light, use the product right away after mixing, and not store, freeze, or refrigerate it after mixing. [2]

Those label instructions apply to the approved products and supplied components. They should not be copied onto compounded preparations, research powders, or third-party products, where the official label, manufacturing controls, and validated handling instructions may not apply. [1][2]